Posts

Posted on

New Super-Telephoto Lens From Olympus Enables 1000mm[1] Equivalent Handheld Shooting

Introducing the M.Zuiko® Digital ED 150-400mm F4.5 TC1.25x IS PRO Lens

PR Newswire

CENTER VALLEY, Pa., Nov. 17, 2020 /PRNewswire/ — Olympus is pleased to introduce the M.Zuiko Digital ED 150-400mm F4.5 TC1.25x IS PRO, a high-resolution, super telephoto zoom lens, delivering unrivaled portability, imaging power and all-weather performance. Equipped with a built-in 1.25x teleconverter, this lens covers a powerful focal length of 300-1000mm equivalent1, and is only 4.1lbs and 12.4 inches in length. Leave the tripod at home. The high-performance 5-Axis Sync IS delivers the world’s most effective 8 shutter speed steps[2] of compensation, enabling up to 1000mm equivalent1 handheld super telephoto shooting. When paired with the optional M.Zuiko Digital 2x Teleconverter MC-20, this Micro Four Thirds® System ultra-zoom lens is capable of up to 2000mm equivalent1 super telephoto shooting. For detailed product specifications, visit: https://www.getolympus.com/lenses/m-zuiko-150-400mm-f4-5-tc-1-25x-is-pro.html.

Ultimate Super-Telephoto Optical Performance

Lens construction consists of 28 elements in 18 groups, including a newly developed large-diameter EDA lens[3] and four Super ED lenses[4], reducing flares and color bleeding across the entire zoom range, and delivering superb edge-to-edge resolution and clarity. Olympus’ renowned Z Coating Nano technology is employed to suppress reflective light and provide sharp, clear image quality, even in difficult shooting environments, such as backlit scenes. The lens body features a built-in 1.25x teleconverter, maintaining high optical performance while enabling up to 1000mm equivalent1 handheld super telephoto shooting, simply by flipping down the teleconverter. Additionally, the lens is compatible with optional M.Zuiko Digital MC-14 1.4x and MC-20 2x teleconverters. When paired with the MC-20, this lens is capable of up to2000mm equivalent1 super telephoto shooting. This lens features a close focusing distance of 1.3 m across the entire zoom range and close-up shooting performance with a maximum image magnification of 0.57x1, which increases to 0.71x1 when using the built-in teleconverter, for those who enjoy tele macro shooting.

Focal Length

35mm Equivalent

Max Aperture

Value

Max Image

Magnification

35mm Equivalent

M.Zuiko Digital ED 150-400mm F4.5 TC1.25x IS PRO

300-800mm

(150mm-400mm)

F4.5

X0.57

(x0.29)

With Built-in 1.25x Teleconverter

375-1000

(187.5mm-500mm)

F5.6

X0.71

(x0.36)

With Built-in 1.25x Teleconverter and optional MC-14 1.4x Teleconverter

525-1400mm

(262.5mm-700mm)

F8.0

X1.01

(x0.5)

With Built-in 1.25x Teleconverter and optional MC-20 2x Teleconverter

750mm-2000mm

(375mm-1000mm)

F11

X1.43

(x0.71)

Unrivaled Portability and Weather Sealed Design
 

The lens barrel is designed using magnesium alloy and the lens hood with a lightweight carbon fiber to ensure that the center of gravity of the lens does not shift, due to imbalance, when the lens hood is used. Use of optimal materials in each area of the lens maintains strength and precision while delivering a compact, lightweight design with a length of 12.4 inches and weight of only 4.1 lbs.[5], for unprecedented mobility. Pairing this lens with the superb dustproof, splashproof, and freezeproof performance of the Olympus OM-D® E-M1X enables the user to continue shooting in punishing environments such as rain and snow with peace of mind. Compared with the black coating on conventional lenses, the heat-resistant coating of this PRO lens efficiently reflects the infrared rays of sunlight, keeping temperatures inside the lens from rising, even in blazing hot weather, for stable optical performance. The front element of the lens features a fluorine coating to provide a smooth and scratch resistant surface and allows easier cleaning for better maintenance.

Powerful Image Stabilization and Fast, High-Precision Autofocus

The M.Zuiko Digital ED 150-400mm F4.5 TC1.25x IS PRO lens supports 5-Axis Sync IS, and at 300mm equivalent1 delivers the world’s most effective 8 shutter speed steps2 of image stabilization, and at 1000mm equivalent1 delivers up to 6 shutter speed steps[6] of image stabilization, when using the built-in teleconverter. This powerful image stabilization is also available in the super telephoto range, up to 2000mm equivalent1, when paired with the optional MC-20 Teleconverter. High image quality hand-held shooting is possible, making it perfect for wildlife, birding, nature photography and more. Olympus proprietary high-precision lens thinning technology makes the focusing lenses lightweight, delivering fast and precise focusing across the entire zoom range.

Other Features

  • Inner zoom system maintains the original length of the lens, even when increasing zoom magnification
  • Constructed with rubberized zoom/focusing ring, for comfortable operation
  • Preset focus function allows the user to set and recall favorite focal positions
  • Tripod base plate in a shape and size that is easy to carry
  • Strap eyelets are installed to improve transportability and reduced load on the lens mount
  • Rubber lens end cover, designed to prevent scratches on the front of the lens
  • Compatible with Focus Stacking[7], allowing the user to create composite images with crisp focus from front to back

Accessories

Zuiko PRF-ZD95 PRO Protection Filter (sold separately)
This protection filter features ZERO Coating to suppress flares and ghosts from reflections and easy-to-clean, fluorine-coated, black-edged glass. The filter features a satin, glare-reducing black aluminum frame.
MSRP: $324.99 (US)/$429.99 (CAD)

LH-115 Lens Hood (included)
This lightweight carbon fiber lens hood boasts excellent durability. A flocked finish on the inside of the hood prevents internal reflection.

CSS-P121 Lens Strap (included)
This lens strap is for exclusive use with a super-telephoto lens. It is made of mesh material to prevent discomfort, has excellent cushioning, and an anti-slip texture.

LC-115 Lens Cap (included)
This cloth cover-style lens cap is easy to attach and remove for quick shooting.

LSC-1642 Lens Case (included)
This purse-string lens case features three-layer construction that protects the lens and can be used to store the lens with lens hood, lens cap, protection filter, and teleconverter attached for safe storage and travel.

Pricing, Configurations, Availability & Specifications
The Olympus M.Zuiko Digital ED 150-400mm F4.5 TC1.25x IS PRO lens comes packaged with the LH-115 lens hood, CSS-P121 lens strap, LC-115 lens cap and LSC-1642 lens case. It is available for pre-order now for $7,499.99 USD and $9,999.99 CAD at participating local authorized retailers, or at www.getolympus.com, and will begin shipping in late January, 2021.

Journalists who are interested in more information should contact Jennifer Colucci, Olympus America Inc., [email protected].

ABOUT OLYMPUS AMERICA INC.
Olympus is passionate about the solutions it creates for the medical, life sciences, and industrial equipment industries, as well as cameras and audio products. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, ensuring public safety, and capturing images of the world.

Olympus’ imaging business empowers consumers and professionals alike with innovative digital cameras, lenses, audio recorders, and binoculars. The company’s precision optics and groundbreaking technology open up new possibilities for capturing life’s most precious moments. For more information, visit www.getolympus.com.

All trademarks and registered trademarks listed herein are the property of their respective holders, in the U.S. and/or other countries.

Olympus…True to You. True to Society. True to LIFE.

© 2020 Olympus America Inc.

1 35mm equivalent
2 According to CIPA standards. When attached to OM-D E-M1X, with yaw and pitch applied to camera, half-press IS: Off, and focal length set to 150mm (35mm equivalent f=300mm), As of November 17, 2020
3 Extra-low Dispersion Aspherical lens
4 Super Extra-low Dispersion lens
5 Excluding lens cap, lens rear cap, and lens hood
6 According to CIPA standards. When attached to OM-D E-M1X, with yaw and pitch applied to camera, half-press IS: Off, and focal length set to 500mm when using the built-in teleconverter 1.25x (35mm equivalent f=1000mm)
7 Visit the Olympus website for compatible camera information

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/new-super-telephoto-lens-from-olympus-enables-1000mm1-equivalent-handheld-shooting-301174287.html

SOURCE Olympus

Posted on

Flex LNG Third Quarter 2020 Presentation

Flex LNG Third Quarter 2020 Presentation

Please find enclosed the presentation of Flex LNG Ltd.’s third quarter 2020 results to be held through webcast/conference call November 17, 2020 at 3:00 p.m. CET (9:00 a.m. EST)

Attend by Webcast:

Use to the follow link prior to the webcast:



https://edge.media-server.com/mmc/p/noymzjrh


Attend by Conference Call:

Applicable dial-in telephone numbers are as follows:

Norway: +47 21 03 39 22

United Kingdom: +44 (0) 203 0095 709

United Kingdom (local): 0844 4936 766

United States (Toll Free): +1 866 2801 157

Confirmation Code: 5888874

The presentation material which will be used in the teleconference/webcast can be downloaded on www.flexlng.com and replay details will also be available at this website.

Attachment



Posted on

Flex LNG Q3, 2020 Earnings Release

November 17, 2020 – Hamilton, Bermuda

Flex LNG Ltd. (“Flex LNG” or the “Company”) today announced its unaudited financial results for the third quarter and nine months ended September 30, 2020.

Highlights:

  • Revenues of $33.1 million for the third quarter 2020, compared to $25.8 million for the second quarter 2020.
  • Net income of $3.8 million and earnings per share of $0.07 for the third quarter 2020, compared to a net loss of $6.7 million and loss per share of $0.12 for the second quarter 2020.
  • Average Time Charter Equivalent (“TCE”) rate of $46,569 per day for the third quarter 2020, compared to $46,588 per day for the second quarter 2020.
  • Adjusted EBITDA of $21.9 million for the third quarter 2020, compared to $17.4 million for the second quarter 2020.
  • Adjusted net income of $1.2 million for the third quarter 2020, compared to adjusted net loss of $0.7 million for the second quarter 2020.
  • Adjusted earnings per share of $0.02 for the third quarter 2020, compared to adjusted loss per share of $0.01 for the second quarter 2020.
  • In July 2020, the Company took delivery of its seventh newbuilding LNG carrier, Flex Aurora, which commenced an 11 month firm charter in August.
  • In August 2020, the Company took delivery of its eighth newbuilding LNG carrier, Flex Artemis, which commenced a long-term charter to Clearlake Shipping, a subsidiary of the Gunvor Group, for up to ten years, where the first five years are firm.
  • In September 2020, the Company took delivery of its ninth newbuilding LNG carrier, Flex Resolute, which commenced an 11 month firm charter.
  • In October 2020, the Company took delivery of its tenth newbuilding LNG carrier, Flex Amber, which  commenced a 12 month firm charter with options to extend by an additional two years.
  • The Board of Directors has declared a cash dividend for the third quarter of $0.10 per share.

Øystein M Kalleklev, CEO of Flex LNG Management AS, commented:

“The third quarter was a very eventful quarter for Flex LNG. We took delivery of Flex Aurora in July, Flex Artemis in August, Flex Resolute in September and subsequent to quarter-end we took delivery of Flex Amber in October. With these additions, our fleet now consists of ten state-of-the-art large LNG carriers. All these newbuildings have been secured on fixed and variable charters, evidencing the attractiveness of our modern efficient vessels.

Our trading results were in line with the second quarter and our guidance. We have thus been able to trade our vessels at cash break-even levels during very challenging market conditions, despite significant spot exposure and operational restrictions caused by Covid-19. We are pleased that our vessels have been operating with 100 per cent up-time, and that we have managed to minimize extended stays on our vessels for our seafarers with 32 crew changes conducted in the period May to October.

During the autumn, both gas and freight markets have recovered, and we are thus expecting our TCE to increase to $70-75,000 per day for the fourth quarter. Improved trading results together with a strong financial position, which includes financing for the three remaining newbuildings, also enables us to reinstate the dividend.  ”

Third Quarter 2020 Result Presentation

Flex LNG will release its financial results for the third quarter 2020 on Tuesday November 17, 2020. In connection with the earnings release, a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. EST). In order to attend the webcast and/or conference call you may do one of the following:

Attend by Webcast:

Use to the follow link prior to the webcast: https://edge.media-server.com/mmc/p/noymzjrh

Attend by Conference Call:

Applicable dial-in telephone numbers are as follows:
Norway: +47 210 33 922

United Kingdom: +44 (0) 203 0095 709
United Kingdom (local): 0844 493 6766
United States, New York: +1 646 787 1226
United States: +1 866 280 1157

Confirmation Code: 5888874

The presentation material which will be used in the teleconference/webcast can be downloaded on www.flexlng.com and replay details will also be available at this website.

For further information, please contact:

Harald Gurvin, CFO

Telephone: +47 23 11 40 00

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “target,” “project,” “likely,” “may,” “will,” “would,” “could” and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties. Although management believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond the Company’s control, there can be no assurance that the Company will achieve or accomplish these expectations, beliefs or projections. The Company undertakes no obligation, and specifically declines any obligation, except as required by law, to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

In addition to these important factors, other important factors that, in the Company’s view, could cause actual results to differ materially from those discussed in the forward-looking statements include: unforeseen liabilities, future capital expenditures, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand in the LNG tanker market, the length and severity of the COVID-19 outbreak, the impact of public health threats and outbreaks of other highly communicable diseases, changes in the Company’s operating expenses, including bunker prices, dry-docking and insurance costs, the fuel efficiency of the Company’s vessels, the market for the Company’s vessels, availability of financing and refinancing, ability to comply with covenants in such financing arrangements, failure of counterparties to fully perform their contracts with the Company, changes in governmental rules and regulations or actions taken by regulatory authorities, including those that may limit the commercial useful lives of LNG tankers, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessel breakdowns and instances of off-hire, and other factors, including those that may be described from time to time in the reports and other documents that the Company files with or furnishes to the U.S. Securities and Exchange Commission (“Other Reports”).  For a more complete discussion of certain of these and other risks and uncertainties associated with the Company, please refer to the Other Reports.

Attachment



Posted on

Innate Pharma Reports Third Quarter 2020 Financial Results and Business Update


  • Lacutamab


    granted PRIME designation in


    Sézary


    Syndrome by the European Medicines Agency

  • Monalizumab


    Phase 3 study


    ini


    tiated


    , triggering $50 million milestone payment

  • Cash position of


    €


    163.6


    million



    1



    as of


    September 30


    , 2020

MARSEILLE, France, Nov. 17, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its revenues and cash position for the first nine months of 2020.

“
In November
, w
e
were
very
pleased
that our lead proprietary asset,
l
acut
a
mab
,
was awarded PRIME designation
in
S
é
zary
Syndrome
by the European Medicines A
gency
, which follows the US Fast Track designation by the FDA last year
.  Lacutamab is an important part of our strategy to build a focused proprietary pipeline, and these regulatory milestones further validate the unmet need in this patient population,” said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. “In addition, the Phase 3 monalizumab clinical trialrecently initiated by AstraZeneca is an important achievement for the Company, as it bothvalidates our scientific approach whilefortifying our cash position until the end of 2022. Collectively, these milestones are strong proof points in executing on our strategy and accelerating our efforts to deliver meaningful medicines to patients.”  

Third quarter 2020 and
post-period events
:


Lacutamab


(IPH4102, anti-KIR3DL2 antibody):

  • The Company recently announced that the European Medicines Agency (EMA) has granted PRIME designation to lacutamab for the treatment of patients with relapsed or refractory Sézary syndrome (SS) who have received at least two prior systemic therapies.
  • The TELLOMAK Phase 2 clinical trial, which is evaluating the efficacy and safety of lacutamab in patients with advanced cutaneous T-cell lymphomas, is now fully open to enrollment.


Monalizumab


(anti-NKG2A antibody), partnered with AstraZeneca:

  • As recently announced, AstraZeneca has dosed the first patient in its Phase 3 clinical trial, INTERLINK-1, evaluating monalizumab in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors. Dosing of the first patient in this trial, which occurred in October 2020, has triggered a $50 million milestone upcoming payment from AstraZeneca to Innate. Upon this milestone payment, the Company will have received a total of $400 million to date from the AstraZeneca partnership.
  • Updated data from the IPH2201-203 Phase 2 trial regarding patients previously treated with a platinum-based chemotherapy and a PD(L)1 inhibitor will be presented via an e-poster at the ESMO Immuno-Oncology Virtual Congress in December 2020.


Avdoralimab


in Inflammation


(IPH5401, anti-C5aR antibody):

  • The first patient has been dosed in the investigator-sponsored Phase 2 clinical trial in bullous pemphigoid (BP) where the C5aR1 pathway has been shown to be involved in the physiopathology of the disease. The trial is investigating the clinical efficacy of avdoralimab in addition to topical steroids compared to topical steroids alone in BP patients. More information on this study can be found at clinical trials.gov.


Avdoralimab


in


COVID-19:

  • The investigator-sponsored Phase 2 clinical trial, FORCE (FOR COVID-19 Elimination), is ongoing. A third cohort was recently added to the trial, which is addressing COVID-19 related Acute Respiratory Distress Syndrome (ARDS) patients requiring mechanical ventilation. More information on this study can be found at clinical trials.gov.
  • The investigator-sponsored Phase 2 clinical trial, ImmunoONCOVID-20, has resumed. This study is exploring the potential efficacy of monalizumab and avdoralimab amongst other treatment arms, against COVID-19 in cancer patients with mild symptoms and pneumonia respectively.


Lumoxiti


, a first-in-class marketed product for the treatment of relapsed or refractory hairy cell leukemia:

  • The global COVID-19 pandemic and slower adoption rate continues to impact the sales of Lumoxiti in 2020.
  • As previously stated, following completion of the transition of US Lumoxiti commercial operations from AstraZeneca, sales will be fully booked by Innate beginning in Q4 2020. 
  • The Lumoxiti EU regulatory decision remains on track for 1H 2021.

Financial result
s:

Cash, cash equivalents and financial assets of the Company amounted to €163.6 million as of September 30, 2020. As it is a post closing event, the $50 million milestone upcoming payment for the first patient dosed in the Interlink-1 Phase 3 study of monalizumab are not included in those figures. Financial liabilities amounted to €19.8 million.

For the nine-month periods ended September 30, 2019 and 2020, revenue from collaboration and licensing agreements mainly results from the spreading of the initial payments received under our agreements with AstraZeneca. Due to accounting rules and the timing of costs related to development activities under the collaboration with AstraZeneca, the recognition of this revenue can vary on a quarter by quarter each year. As a reminder, this has no impact on cash. Revenues for the first nine-months of 2020 amounted to €33.6 million, compared to €65.4 million for the same period in 2019.

About Innate Pharma:

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code

Ticker
code

LEI 		FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors
:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:


Investors

Innate Pharma        
Tel.: +33 (0)4 30 30 30 30
[email protected]
Media

Innate Pharma

Tracy Rossin (Global/US)
Tel.: +1 240 801 0076
[email protected]

ATCG Press
Marie Puvieux (France)
Tel.: +33 (0)9 81 87 46 72
[email protected]

1 Including short term investments (€15.5 million) and non-current financial instruments (€37.3 million). Not including the $50mn milestone payment from AstraZeneca for the first patient dosed in the Interlink-1 Phase 3 study of monalizumab.



Posted on

GWTI Responds to RRC Gas Flaring Reduction Moves – Update

ARLINGTON, Texas, Nov. 17, 2020 (GLOBE NEWSWIRE) — Greenway Technologies, Inc. (OTCQB: GWTI), (the “Company”), an advanced gas-to-liquids (“GTL”) technology development company, today responds to the November 4, 2020 Texas Railroad Commission (RRC) announcement aimed at further reducing flaring from oil and gas sites across the state.

The agency’s commissioners announced approval of revamped exceptions associated with Statewide Rule 32 which states that “all gas from any oil well, gas well, gas gathering system, gas plant or other gas handling equipment shall be utilized for purposes and uses authorized by law.”

RRC commissioners approved a revamped Form R-32 used for exceptions to Rule 32. Among the changes are a reduction in the period of time for a flaring exception, and incentives for operators that deploy technologies to reduce the amount of gas flared, as well as more strict reporting requirements.

GWTI offers a modular, relocatable, technology solution that converts flared gas into valuable end products including liquid fuel, water, and long chain organic hydrocarbons which was developed in conjunction with the University of Texas at Arlington. The patented technology has the potential to reduce flaring in Texas as well as to transform the global energy landscape by facilitating the conversion of previously uneconomic and often polluting natural gas into valuable fuels and chemicals.

Kent Harer, GWTI CEO stated that “GWTI has devoted itself over the last ten years to develop and prove this technology based on proprietary processes and procedures to perfect its clean fuels gas-to-liquids solution. We are pleased to offer this unique technology solution to support Texas’ efforts to reduce gas flaring. GWTI’s solution not only reduces or eliminates gas flaring, it also facilitates the monetization of the source gas paying for itself.”

About Greenway Technologies, Inc.

Based in Arlington, Texas, the Company, through its wholly owned subsidiary, Greenway Innovative Energy, Inc., is engaged in the research and development of proprietary GTL syngas conversion systems that can be scaled to meet oil and gas field production requirements. The Company’s patented technology has been integrated into its recently completed first-generation commercial G-Reformer™ unit, a unique component used to convert natural gas into synthesis gas. When combined with a FT reactor and catalyst, G-Reformer™ units can be deployed to process a variety of natural gas streams including pipeline gas, associated gas, flared gas, vented gas, coal-bed methane, and biomass to produce fuels including gasoline, diesel, jet fuel, and methanol. When derived from natural gas, these fuels are incrementally cleaner than conventionally produced oil-based fuels. For additional information about the Company, visit www.gwtechinc.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based only on information available to the Company as of the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the Securities and Exchange Commission, those associated with the uncertainty of obtaining future technology licensing agreements or sales, and those related to the ability of the Company to: (i) integrate the Company’s technology with existing plant technologies, (ii) produce and sell liquid fuels from such facility, and (iii) receive certification of the Company’s intellectual property. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events, or otherwise, except as required by law.

###

Investors & Analysts Contact:
Greenway Investor Relations
800-289-2515
[email protected]
SEC filings can be found at:
http://gwtechinc.com/SEC-filings/

For more information, visit GWTI’s website: www.gwtechinc.com



Posted on

Wipro and Cisco collaborate to deliver SD-WAN Transformation services to Olympus

Wipro and Cisco collaborate to deliver SD-WAN Transformation services to Olympus

EAST BRUNSWICK, N.J. & BANGALORE, India–(BUSINESS WIRE)–
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it will deliver managed Software-Defined Wide Area Network (SD-WAN) transformation services to Olympus leveraging Cisco technology.

Headquartered in Tokyo, Japan, Olympus is passionate about the solutions it creates for the medical, life sciences, and industrial equipment industries, as well as cameras and audio products. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, ensuring public safety, and capturing images of the world.

As a part of this engagement, Wipro will use its proprietary managed network services solution, #WANFreedom to re-architect Olympus’s WANs and enable support across distributed applications in a hybrid multi-cloud environment. The new network infrastructure will drastically improve Olympus’s application performance to deliver superior end user experience, resulting in increased business productivity, agility and reduced costs for IT.

The managed services model allows Wipro to deliver optimal cost-effectiveness and reliability to its customers by monitoring, maintaining, and managing services continuously. Wipro’s managed SD-WAN #WANFreedom services are enabled by Cisco’s global Secure SD-WAN Managed Services Partner (MSP) Program.

Stephen Kneebone, Global CIO, Olympus,said,“As we move into a world where businesses are focused on being more resilient by accelerating digital transformation, we believe that we are keeping pace with the change. Our cloud adoption and application migration initiatives demand high performance from the network. With Wipro, we have embarked on our WAN transformation journey that improves application experience and reduces our OPEX as Wipro’s #WANFreedom solution standardizes our global WAN spread across 40+ countries. Wipro’s centralized platform for contract management will consolidate our service providers and is expected to provide up to a 30 percent cost reduction.”

Kiran Desai, Senior Vice President, Cloud and Infrastructure Services, Wipro Limited, said, “We are excited to be selected by Olympus as their SD-WAN transformation partner. Wipro’s #WANFreedom provides comprehensive lifecycle services spanning consulting, planning and design, implementation, and managed network services. Our as-a-service model powered by integrated automation platform will create a cognitive digital networking infrastructure for Olympus, which is secure and dynamic. Its enhanced capabilities will help Olympus gain flexibility to access multi-cloud services, reduce overhead, and support new applications in its digital transformation journey.”

Scott Harrell, Senior Vice President and General Manager of Cisco’s Intent-Based Networking Group,said, “As organizations adopt the cloud for key applications, their WAN architecture must also evolve to provide the best experience for their users and improved efficiency for their organizations. Agility and security are paramount in this transition. Through Cisco’s secure SD-WAN technology and Cisco’s new Service Creation Program for partners, Wipro can help customers like Olympus secure their connectivity to multiple clouds, optimize their application experiences and accelerate their digital transformation journeys.”

About Wipro Limited

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading global information technology, consulting and business process services company. We harness the power of cognitive computing, hyper-automation, robotics, cloud, analytics, and emerging technologies to help our clients adapt to the digital world and make them successful. A company recognized globally for its comprehensive portfolio of services, strong commitment to sustainability, and good corporate citizenship, we have over 180,000 dedicated employees serving clients across six continents. Together, we discover ideas and connect the dots to build a better and a bold new future. For more information, please visit www.wipro.com.

Forward-looking and Cautionary Statements

The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry. The conditions caused by the COVID-19 pandemic could decrease technology spending, adversely affect demand for our products, affect the rate of customer spending and could adversely affect our customers’ ability or willingness to purchase our offerings, delay prospective customers’ purchasing decisions, adversely impact our ability to provide on-site consulting services and our inability to deliver our customers or delay the provisioning of our offerings, all of which could adversely affect our future sales, operating results and overall financial performance. Our operations may also be negatively affected by a range of external factors related to the COVID-19 pandemic that are not within our control. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.

Media Contact:

Shraboni Banerjee

Wipro Limited

[email protected]

KEYWORDS: New Jersey North America United States Asia Pacific India Japan

INDUSTRY KEYWORDS: Software Networks Professional Services Internet Hardware Data Management Technology Security Other Professional Services Human Resources Other Technology Consulting Telecommunications

MEDIA:

Logo
Logo
Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Garrett Motion Inc. of Class Action Lawsuit and Upcoming Deadline –  GTX; GTXMQ

NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Garrett Motion Inc.  (“Garrett” or the “Company”) (NYSE: GTX; OCTMKTS: GTXMQ).   The class action, filed in United States District Court for the Southern District of New York, and docketed under 20-cv-09279, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Garrett securities between October 1, 2018 and September 18, 2020, inclusive (the “Class Period”).  Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased Garrett securities during the class period, you have until November 24, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 



[Click here for information about joining the class action]

Garrett designs, manufactures, and sells turbocharger, electric-boosting, and connected vehicle technologies for original equipment manufacturers and the aftermarket.  In October 2018, the Company formed as a spin-off of the Transportation Systems business of Honeywell International Inc. (“Honeywell”).

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants failed to disclose to investors that: (i) because of Garrett’s agreement to indemnify and reimburse Honeywell for certain asbestos-related liability, the Company was saddled with an unsustainable level of debt; (ii) as a result, Garrett had a highly leveraged capital structure that posed significant challenges to its overall strategic and financial flexibility; (iii) as a result of the foregoing, Garrett’s ability to gain or hold market share was impaired; (iv) as a result of the foregoing, the Company was reasonably likely to seek bankruptcy protection; and (v) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 26, 2020, before the market opened, the Company disclosed that its “leveraged capital structure poses significant challenges to its overall strategic and financial flexibility and may impair its ability to gain or hold market share in the highly competitive automotive supply market, thereby putting Garrett at a meaningful disadvantage relative to its peers.”  Garrett further stated that its “high leverage is exacerbated by significant claims asserted by Honeywell against certain Garrett subsidiaries under the disputed subordinated asbestos indemnity and the tax matters agreement.”

On this news, Garrett’s stock price fell $3.04 per share, or over 44%, to close at $3.84 per share on August 26, 2020, thereby damaging investors.

On Sunday, September 20, 2020, Garrett announced that it had filed for Chapter 11 bankruptcy.

On Monday, September 21, 2020, the New York Stock Exchange (“NYSE”) announced that it would commence proceedings to delist Garrett’s stock from the NYSE after the Company’s disclosure that it had filed for bankruptcy.

On this news, Garrett’s stock began trading over-the-counter and closed at $1.76 per share on September 22, 2020, and over 12% decline from the closing price on September 18, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980



Posted on

eXp World Holdings Expands Real Estate Operations Into India

One of the Fastest-growing Real Estate Platforms Extends Opportunity to Over 1 Million Agents in India Market

BELLINGHAM, Wash., Nov. 17, 2020 (GLOBE NEWSWIRE) — eXp World Holdings (Nasdaq: EXPI), the holding company for eXp Realty, one of the fastest-growing residential and commercial real estate companies in the world, today announced it has expanded its collaborative, cloud-based real estate brokerage model into India, under the eXp India banner. The addition of residential and commercial brokerage operations in India represents the fifth international expansion for the company, which is headquartered in the United States. In addition to its robust U.S. presence, eXp Realty also operates in Canada, the United Kingdom, Australia, and South Africa, with more than 38,000 agents across the globe.

eXp Realty offers a unique financial model for residential and commercial real estate agents, going beyond attractive commissions to provide its agents with revenue share and equity ownership opportunities. The partnership model also offers proprietary marketing resources, including the company’s cloud-based virtual environment and customized technology platform that enhances virtual prospecting, sales, training and communications for agents.

“We are excited to bring our innovative and proven model to India. Given its pool of over 1 million agents, India is one of the most dynamic real estate markets in the world and is perfectly poised to benefit from our agent-centric model,” said Michael Valdes, President of eXp Global. “In advance of our official launch, we have already received a phenomenal response after formally establishing operations and our preliminary marketing efforts. In addition to increased revenue opportunities the model brings to agents in India, our focus will be to provide access to our cloud-based brokerage and virtual technology to help deliver valuable marketing resources and position our agents for the future of real estate.”

“India has never seen a model like this before, which I believe will change the traditional landscape of the industry,” said Shashank Vashishtha, Designated Managing Broker in India. “eXp India will be a game-changer for both consumers and agents.”  

Similar to the U.S. model, eXp Realty and the global division anticipates a similar trajectory for India’s real estate industry to utilize a model that not only offers generous commissions, but incentivizes agents to attract other agents through eXp’s multi-layered compensation model.

“Our decision to expand into the growing India market is a direct result of the robust growth we’ve experienced in the U.S. and other high-value international locations,” said Jeff Whiteside, CFO and Chief Collaboration Officer of eXp World Holdings. “Over the last five years, we’ve grown our revenue at a compounded annual growth rate of over 100%, and recently, reported record financial results and profitability in the third quarter of 2020. We expect to continue this momentum by extending our incentivizing model to markets capable of the success we’ve had domestically, and believe India aptly illustrates that opportunity.”

The company’s presence in India will encompass a national footprint, including all major cities and states. India represents one of five countries eXp Global has identified for expansion by the end of 2020. South Africa launched in October 2020 and the remaining countries include France, Mexico and Portugal.

About eXp World Holdings, Inc.

eXp World Holdings, Inc. (Nasdaq: EXPI) owns eXp Realty and Virbela.

eXp Realty, The Real Estate Cloud Brokerage, is one of the fastest-growing, global residential real estate companies with more than 38,000 agents in the United States, Canada, the United Kingdom, Australia and South Africa. As a subsidiary of a publicly traded company, eXp Realty uniquely offers real estate professionals within its ranks opportunities to earn eXp World Holdings stock for production and contributions to overall company growth.

Virbela is an immersive technology platform for business, events and education. Its modern, cloud-based environment provides a virtual experience for workers, attendees, students and more to communicate, collaborate, meet and socialize. For more information, visit the company’s website at virbela.com.

For more information, please visit the company’s website at https://expworldholdings.com.

Safe Harbor Statement

The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Such forward-looking statements speak only as of the date hereof, and the company undertakes no obligation to revise or update them. These statements include, but are not limited to, statements about the economic and social effects of the COVID-19 pandemic; continued growth of our agent and broker base; expansion of our residential real estate brokerage business into foreign markets; demand for remote working and distance learning solutions and virtual events; development of our new commercial brokerage and our ability to attract commercial real estate brokers; and revenue growth and financial performance. Such statements are not guarantees of future performance. Important factors that may cause actual results to differ materially and adversely from those expressed in forward-looking statements include changes in business or other market conditions; the difficulty of keeping expense growth at modest levels while increasing revenues; and other risks detailed from time to time in the company’s Securities and Exchange Commission filings, including but not limited to the most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K.

Media Relations Contact:

eXp World Holdings, Inc.
[email protected]

India Media Relations Contact:

Deepali Gusain
[email protected]

Investor Relations Contact:

Greg Falesnik
MZ Group – MZ North America
[email protected]



Posted on

Buckreef Test Plant Supports Production Expansion

VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) — Tanzanian Gold Corp. (TSX: TNX); (NYSE American: TRX) (“Tanzanian Gold” or the “Company”) is pleased to provide an update on the 5tph (tons per hour) test plant. As previously reported the plant reached commercial production of gold on June 17, 2020. Since then the plant has operated continuously 7 days a week with two 12-hour shifts per day and has produced a total of 427.9 oz of gold. Here are some of the key performance metrics in the period June 30, 2020 to October 30,2020:

  • 250,810 tons of waste and topsoil removed and stockpiled
  • 21,900 tons of ore mined
  • 10,040 tons ore crushed – wet
  • 9,078 tons ore milled – dry
  • 137 total days operated
  • plant availability has ranged from 73.1% to 94.6 %
  • the average recovery has been quiet steady at 82%

The 5tph oxide test plant has been a substantial success on several levels. First, operation of the plant to date proves the viability of the Buckreef Gold Project (“Buckreef”) to produce gold and therefore provides a considerable de-risking of the mine building efforts at Buckreef. A number of important tests have been conducted providing data for the operation and confirming the flowsheet for expansion of the processing plant to the rate of 40tph (15,000 oz. to 20,000 oz. of gold production per year). The main tests to date are:

  • Retention times & associated cyanide and lime consumption
  • Grind-leach tests & grind media consumption
  • Impact of aeration/oxidation
  • Optimizing elution
  • Effect of preg-robbing, these tests are still in progress

Additionally, the plant has been used to train and develop a crew that will be ready to operate the larger 40tph plant when it comes online. Start-up and operation of the test plant has provided months of experience in: (i) understanding the oxide deposit; (ii) areas of mining and earth moving; (iii) stockpile management; (iv) grade blending control; (v) equipment and materials procurement; (vi) local content regulations; (vii) security; and more. The Company has initiated construction of a large tailings facility to accommodate the targeted expansion of the oxide plant.

As work advances rapidly with the oxide operation, Tanzanian Gold continues to advance the sulphide mine Final Feasibility Study, which is targeted to produce 150,000 oz. to 175,000 oz. of gold production per year. The Company has begun the process of pit modeling, one of the foremost components of the Final Feasibility Study. SGS is proceeding with the metallurgical studies to refine the flowsheet for the sulphide plant.

Finally, Tanzanian Gold continues to focus on the value creating exploration opportunities at Buckreef, with a variety of planned drilling programs. The programs include: (i) drilling at ultra-deep levels; (ii) drilling new oxide targets; (iii) infill drilling to upgrade ounces currently in the Inferred category; and (iv) a step-out drilling program in the Northeast Extension.

Mr. James E. Sinclair, Executive Chairman of Tanzanian Gold, commented “The exceptional performance of the test plant has laid a firm technical foundation and has helped to de-risk our plans to a build a much larger plant”, Mr. Sinclair went on to comment “ We have every expectation that we will be producing in the range of 15,000 to 20,000 oz. of gold production per year with the new plant and after start up we could be in a position to consider an expansion of this plant.”

Mr. James E. Sinclair went on to note that “critically, we have now become a gold producer. The financing arrangements we have previously announced will help to ensure the rapid expansion of production such that we can expect to reach our goal of becoming cash flow positive.”

About Tanzanian Gold Corporation 

Tanzanian Gold Corporation is building a significant gold project at the Buckreef site in Tanzania that is based on an expanded resource base and the treatment of its mineable reserves in two stand alone plants. An ongoing drill program has, to date, more than doubled the size of Measured and Indicated Resources to 2.036 million ounces. NI 43-101 compliant exploration mining targets have the potential to add up to another 2 million ounces. The Company commenced production from oxides in June 2020 at a new oxide plant and is now anticipating government approval for an expanded oxide plant to the level of 40tph.

 Tanzanian Gold is advancing on three value-creation tracks:

1. Strengthening its balance sheet from expanding near-term production of gold to the range of 15,000 oz. -20,000 oz. of gold production per year from processing oxides:
2. Advancing the Final Feasibility Study for a stand-alone sulphide treating plant that is substantially larger than previously modelled, targeting annual gold production of 150,000 to 175,000 oz.; and
3. Continuing with a drilling program to further test the potential of its resource base by: (i) drilling at ultra-deep levels; (ii) drilling new oxide targets; (iii) infill drilling to upgrade ounces currently in the Inferred category; and (iv) a step-out drilling program in the Northeast Extension.
   

Respectfully Submitted,

James E. Sinclair
Executive Chairman

For further information, please contact Michael Martin, Investor Relations, via email at [email protected], direct line 860-248-0999, or visit the Company website at www.tangoldcorp.com

Please follow us on social media for more updates.

www.Twitter.com/TanzanianGold

www.Linkedin.com/company/Tanzanian-gold-corporation/

www.facebook.com/tanzaniangold

The Toronto
Stock
E
x
chan
g
e a
n
d
NYSE
American
L
LC
ha
v
e
n
o
t
r
e
v
i
ewed
and
do

n
o
t acce
p
t
r
e
sponsibili
t
y
for
the
a
d
equacy
or
accu
r
a
cy of
this
r
e
l
ease

Cautionary
Note
to U
.
S.
Inv
e
sto
r
s – The
U
n
it
e
d Stat
e
s Securities a
n
d Exc
h
a
n
ge
Commission limits
d
isclos
u
re
for
U
.S
. reporting
pu
r
p
os
e
s to
mi
n
eral
d
e
p
osits t
h
at
a
com
p
a
n
y
can
e
c
o
n
omical
l
y
a
n
d
legal
l
y
ex
t
r
act
o
r
p
r
o
du
ce.
W
e may
u
se
cert
a
in te
r
ms on t
h
is
n
e
w
s
r
e
l
e
ase,
s
u
ch as “
r
eserves”,
“
res
ou
rces”,
“geolo
gi
c
reso
u
r
c
es”,
“
p
roven”,
“
p
ro
b
a
b
le”,
“meas
u
red”,
“i
nd
icated”, or
“inf
e
r
re
d
”
w
h
i
c
h
may
not be
c
onsistent
w
ith
the
r
e
s
er
ve d
e
finitions
e
stablish
e
d
by
the
SEC. U
.
S.
Investors
a
r
e
u
r
g
e
d
to consider
close
l
y
the
disclosure
i
n
our
SEC
filings. You
can
r
e
vi
e
w
and
obtain
cop
i
es
of
these
filings
f
r
om
the
SEC’s
w
e
bsite
a
t

h


tt


p


:/


/


www.


s


ec


.


gov/edgar.s


h


t


m


l

This news release contains certain forward-looking statements and forward-looking information. All statements, other than statements of historical fact, included herein are forward-looking statements and forward-looking information that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time-to-time with the British Columbia, Alberta and Ontario provincial securities regulatory authorities.

Certain information presented in this release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on numerous assumptions, and involve known and unknown risks, uncertainties and other factors, including risks inherent in mineral exploration and development, which may cause the actual results, performance, or achievements of the Company to be materially different from any projected future results, performance, or achievements expressed or implied by such forward-looking statements. Investors are referred to our description of the risk factors affecting the Company, as contained in our SEC filings, including our annual report on Form 20-F for more information concerning these risks, uncertainties, and other factors. Such forward-looking statements include, but are not limited to, that the Company will be able to build shareholder value, that the Company will be successful in its expansion at the Buckreef project, that it will be able to build a mine, and that the Company will be able to achieve positive cash flow.